Stronger warnings for TNF blockers

November 2008
Pharmaceutical Representative;Nov2008, Vol. 38 Issue 11, p12
The article reports that the Food and Drug Administration has warned the manufacturers of tumor necrosis factor alpha blockers (TNF) to stabilize the prescribing guides of their drugs in the U.S. According to the article, the said warning will let the physicians and patients to become more cautious in taking these drugs and avoid complicated fungal infections. In addition, such drugs include Humira from Abbott Laboratories Inc., Cimzia from UCB Inc., and Enbrel from Wyeth.


Related Articles

  • Law and the Public's Health. Rosenbaum, Sara; David, Stephanie // Public Health Reports;May/Jun2010, Vol. 125 Issue 3, p494 

    The article discusses a Supreme court case of Wyeth v. Levine in the U.S. on misleading drug labeling. The Supreme Court rejected the argument on implied conflict preemption of Wyeth and finds that Wyeth could have strengthened the Phenergan drug labeling without the Food and Drug...

  • Safety labeling updates & new warnings.  // Formulary;Oct2008, Vol. 43 Issue 10, p381 

    The article reports on the notification of the Food and Drug Administration (FDA) to change the labeling of the drugs adalimumab, certolizumab pegol, etanercept and infliximab. Among the manufacturers who received the warning are Abott, UCB, Amgen/Wyeth and Centocor. The change, according to the...

  • Rules may restrict clinical data claims. Iskowitz, Marc // Medical Marketing & Media;Mar2007, Vol. 42 Issue 3, p9 

    The article focuses on the rules that limits the number of clinical data claims in the U.S. Geoff Levitt, vice president and chief counsel for Wyeth Inc., states that some companies use clinical data to get information specifically on unapproved clinical studies. The Food and Drug Administration...

  • Pneumoccoccal Conjugate Vaccine Gets FDA Priority Review Status.  // Biotech Business;Sep99, Vol. 12 Issue 9, p1 

    Reports that Wyeth Lederle Vaccine's pneumococcal conjugate vaccine was granted priority review status by the United States Food and Drug Administration. Illnesses caused by the pneumococcus bacteria; Disabilities in children caused by meningitis; Number of cases of pneumococcal meningitis and...

  • WALL STREET CHOICE.  // Medical Marketing & Media;Jun2007, Vol. 42 Issue 6, p34 

    The article reports that Wyeth is anticipating the extension of its review of its antidepressant drug Pristiq by the Food and Drug Administration (FDA) in the U.S. It is noted that Wyeth asserts the inclusion of the low dose data will enhance the profile of Pristiq in launching the vasomotor...

  • New delivery system approved for ReFacto.  // Drug Topics;9/27/2004, Vol. 148 Issue 18, p8 

    This article states that the United States Food and Drug Administration approved Wyeth's ReFacto Antihemophilic Factor R2 Kit needle-less reconstitution device.

  • REPORTER'S NOTEBOOK.  // Drug Store News;12/19/2005, Vol. 27 Issue 17, p83 

    The article reports developments in pharmaceutical industry in the U.S. Wyeth has received a panic disorder indication for its antidepressant Effexor XR from the Food and Drug Administration (FDA). The safety of Roche Laboratories' antiviral Tamiflu in children was affirmed by an FDA advisory...

  • product showcase.  // Pharmacy Today;Apr2008, Vol. 14 Issue 4, p20 

    The article evaluates several products including the Pristiq serotin-norepinephrine reuptake inhibitor from Wyeth, the Humira from Abbott Laboratories Inc., and the Nexium from AstraZeneca PLC.

  • Milk brands begin vying for attention.  // Media: Asia's Media & Marketing Newspaper;12/11/2008, p22 

    The article announces that Abbott's decision to appoint a new agency for its infant milk formula in China and Wyeth company's media review are both indicative of the current jostling for position in that sector. It states that the industry has turned on its head by the melamine scandal....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics